An update on the medical therapy of advanced metastatic renal cell carcinoma

Stephan Kruck, Axel S. Merseburger, Georgios Gakis, Mario W. Kramer, Arnulf Stenzl, Markus A. Kuczyk

7 Citations (Scopus)


The effectiveness of multikinase inhibitors in first- and second-line therapy of metastatic renal cell carcinoma (RCC) has been evaluated in various clinical studies. Initial results indicate an increased response rate and a prolonged progression-free survival compared with cytokine-containing therapeutic approaches. The new multitargeted kinase inhibitors sorafenib (Nexavar®/BAY 43-9006) and sunitinib (Sutent®/SUO 11248) interfere mainly with vascular endothelial growth factor and platelet-derived growth factor pathways. Recently, temsirolimus, a specific inhibitor of mammalian target of rapamycin, demonstrated activity in RCC patients with poor prognosis. This review discusses the effectiveness of the most frequently used substances for systemically progressive RCC in consideration of the currently available clinical data.

Original languageEnglish
JournalScandinavian Journal of Urology and Nephrology
Issue number6
Pages (from-to)501-506
Number of pages6
Publication statusPublished - 2008

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)


Dive into the research topics of 'An update on the medical therapy of advanced metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this